Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
23 July 2021Website:
http://cariboubio.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 22:46:26 GMTDividend
Analysts recommendations
Institutional Ownership
CRBU Latest News
NEW YORK, July 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ:CRBU). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Caribou Biosciences develops allogeneic therapies using CRISPR technology, focusing on hematologic cancers and autoimmune diseases. CB-010, CB-011, and CB-012 are in Phase 1 clinical trials, with CB-010 showing promising results for B cell non-Hodgkin lymphoma. Evercore downgraded CRBU's stock due to high COGS concerns, but its superior efficacy and safety might justify higher prices.
NEW YORK , July 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ:CRBU). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. (“Caribou” or the “Company”) (NASDAQ: CRBU). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ:CRBU). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Caribou Biosciences, Inc. is set to present findings from the phase 1 ANTLER study, using CB-010 to treat second-line large B-cell lymphoma patients, at a medical conference in the second quarter of 2024. Early data from the dose escalation phase of the study showed that CB-010 achieved a 90% objective response rate in patients with relapsed or refractory LBCL. FDA approval has been received to begin a phase 1 trial using CB-010 for patients with lupus nephritis and extrarenal lupus, with the trial expected to start by the end of 2024.
Caribou Biosciences, Inc. (CRBU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 1(current)
- 2
What type of business is Caribou Biosciences?
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
What sector is Caribou Biosciences in?
Caribou Biosciences is in the Healthcare sector
What industry is Caribou Biosciences in?
Caribou Biosciences is in the Biotechnology industry
What country is Caribou Biosciences from?
Caribou Biosciences is headquartered in United States
When did Caribou Biosciences go public?
Caribou Biosciences initial public offering (IPO) was on 23 July 2021
What is Caribou Biosciences website?
https://cariboubio.com
Is Caribou Biosciences in the S&P 500?
No, Caribou Biosciences is not included in the S&P 500 index
Is Caribou Biosciences in the NASDAQ 100?
No, Caribou Biosciences is not included in the NASDAQ 100 index
Is Caribou Biosciences in the Dow Jones?
No, Caribou Biosciences is not included in the Dow Jones index
When does Caribou Biosciences report earnings?
The next expected earnings date for Caribou Biosciences is 08 August 2024